DBV Technologies (XPAR:DBV) Construction In Progress : €0.00 Mil (As of Sep. 2024)

View and export this data going back to 2012. Start your Free Trial

What is DBV Technologies Construction In Progress?

DBV Technologies's annual construction in progress increased from Dec. 2021 (€3.89 Mil) to Dec. 2022 (€4.22 Mil) but then declined from Dec. 2022 (€4.22 Mil) to Dec. 2023 (€1.31 Mil).

DBV Technologies Construction In Progress Historical Data

The historical data trend for DBV Technologies's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DBV Technologies Construction In Progress Chart

DBV Technologies Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Construction In Progress

Get a 7-Day Free Trial

11.53

6.44

3.89

4.22

1.31

DBV Technologies Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Construction In Progress	Get a 7-Day Free Trial															-	1.31	-	-	-

DBV Technologies Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

DBV Technologies Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DBV Technologies SA (XPAR:DBV) » Definitions » Construction In Progress

Comparable Companies

Traded in Other Exchanges

DBVTF:USA DBVT:USA 0QAJ:UK DBV:Germany

Address

177-181 avenue Pierre Brossolette, Montrouge, FRA, 92120

Website

http://www.dbvtechnologies.com

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Viaskin targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. Its main product candidate is Viaskin Peanut for the treatment of peanut-allergic patients.